MediciNova Receives Notice of Patent Allowance for MN-221 for Treatment of Acute Exacerbations of Asthma
MediciNova (NASDAQ: MNOV) announced that it has been granted a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers the use of MN-221 for the treatment of acute exacerbations of asthma.
The MN-221 patent maturing from this allowed patent application is expected to expire no earlier than 2030 and includes claims covering the use of MN-221 (bedoradrine) in combination with a standard of care (SOC) treatment regimen. The allowed claims include specific coverage for different routes of administration, including intravenous, oral and inhalation. SOC may include agents such as a beta-agonist bronchodilator or anti-cholinergic or corticosteroid or combinations thereof.